Elliott L. Fineman
Directeur Général chez Planet Biotechnology, Inc.
Postes actifs de Elliott L. Fineman
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Planet Biotechnology, Inc.
 Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | Directeur Général | 01/01/1998 | - |
| President | 01/01/1998 | - |
Historique de carrière de Elliott L. Fineman
Anciens postes connus de Elliott L. Fineman
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Fondateur | 16/07/2009 | 13/09/2011 |
| Corporate Officer/Principal | 06/03/1991 | 16/07/2009 | |
| Cetus Corp. | Corporate Officer/Principal | - | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Directeur des opérations | - | - |
Formation de Elliott L. Fineman
| University of Baltimore | Graduate Degree |
| Georgetown University | Graduate Degree |
| Oberlin College | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Graduate Degree | 2 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Planet Biotechnology, Inc.
Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | Health Technology |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
| Cetus Corp. | Health Technology |
- Bourse
- Insiders
- Elliott L. Fineman
- Expérience
